GRAIL (NASDAQ:GRAL) CEO Robert Ragusa Sells 980 Shares

GRAIL, Inc. (NASDAQ:GRAL) CEO Robert Ragusa sold 980 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $53.01, for a total transaction of $51,949.80. Following the completion of the transaction, the chief executive officer directly owned 649,545 shares of the company’s stock, valued at approximately $34,432,380.45. The trade was a 0.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

GRAIL Price Performance

GRAL opened at $49.82 on Tuesday. The business’s 50-day moving average price is $88.14 and its two-hundred day moving average price is $77.99. GRAIL, Inc. has a 1 year low of $20.44 and a 1 year high of $118.84. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of -4.46 and a beta of 5.21.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($2.44) EPS for the quarter, beating analysts’ consensus estimates of ($3.33) by $0.89. The company had revenue of $43.60 million for the quarter, compared to analyst estimates of $43.33 million. GRAIL had a negative return on equity of 17.58% and a negative net margin of 277.46%. Sell-side analysts anticipate that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GRAL has been the subject of a number of recent research reports. Guggenheim upped their price target on GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. TD Cowen assumed coverage on shares of GRAIL in a report on Thursday, February 19th. They issued a “hold” rating and a $114.00 price objective on the stock. Morgan Stanley cut their price objective on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Thursday, January 22nd. Finally, Canaccord Genuity Group lowered their price target on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, GRAIL currently has a consensus rating of “Hold” and an average target price of $90.17.

Hedge Funds Weigh In On GRAIL

Institutional investors have recently added to or reduced their stakes in the company. Corient Private Wealth LLC raised its position in GRAIL by 60.4% during the fourth quarter. Corient Private Wealth LLC now owns 9,274 shares of the company’s stock worth $794,000 after acquiring an additional 3,491 shares in the last quarter. NWF Advisory Services Inc. lifted its stake in GRAIL by 7.6% in the fourth quarter. NWF Advisory Services Inc. now owns 22,070 shares of the company’s stock valued at $1,889,000 after acquiring an additional 1,564 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of GRAIL in the 4th quarter valued at about $28,000. Banque Transatlantique SA bought a new position in shares of GRAIL in the 4th quarter valued at about $1,969,000. Finally, Virtu Financial LLC acquired a new position in shares of GRAIL during the 4th quarter worth about $370,000.

Key Headlines Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Negative Sentiment: CEO Robert P. Ragusa sold 7,461 shares on March 9 at an average $47.89 (~$357,307), cutting his position by ~1.15%. SEC Filing
• Negative Sentiment: CEO Robert P. Ragusa sold 980 shares on March 5 at $53.01 (~$51,950), a ~0.15% reduction in his stake. SEC Filing
• Negative Sentiment: President Joshua J. Ofman sold 2,937 shares on March 9 at $47.89 (~$140,653), trimming his holding by ~0.67%. SEC Filing
• Negative Sentiment: President Joshua J. Ofman sold 690 shares on March 5 at $53.01 (~$36,577), a ~0.16% reduction in his stake. SEC Filing
• Negative Sentiment: CFO Aaron Freidin sold 2,492 shares on March 9 at $47.89 (~$119,342), reducing his position by ~0.81%. SEC Filing
• Negative Sentiment: CFO Aaron Freidin sold 655 shares on March 5 at $53.01 (~$34,722), a ~0.21% reduction in his holding. SEC Filing

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.